TY - JOUR
T1 - Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T
T2 - Application to brain tumors
AU - Zhou, Jinyuan
AU - Zaiss, Moritz
AU - Knutsson, Linda
AU - Sun, Phillip Zhe
AU - Ahn, Sung Soo
AU - Aime, Silvio
AU - Bachert, Peter
AU - Blakeley, Jaishri O.
AU - Cai, Kejia
AU - Chappell, Michael A.
AU - Chen, Min
AU - Gochberg, Daniel F.
AU - Goerke, Steffen
AU - Heo, Hye Young
AU - Jiang, Shanshan
AU - Jin, Tao
AU - Kim, Seong Gi
AU - Laterra, John
AU - Paech, Daniel
AU - Pagel, Mark D.
AU - Park, Ji Eun
AU - Reddy, Ravinder
AU - Sakata, Akihiko
AU - Sartoretti-Schefer, Sabine
AU - Sherry, A. Dean
AU - Smith, Seth A.
AU - Stanisz, Greg J.
AU - Sundgren, Pia C.
AU - Togao, Osamu
AU - Vandsburger, Moriel
AU - Wen, Zhibo
AU - Wu, Yin
AU - Zhang, Yi
AU - Zhu, Wenzhen
AU - Zu, Zhongliang
AU - van Zijl, Peter C.M.
N1 - Funding Information:
information German Research Foundation (DFG), 445704496; National Research Foundation of Korea (NRF), 2014R1A1A1002716; National Institutes of Health, P41EB015909; P41EB029460; R01AG069179; R01CA228188; R01EB015032; R37CA248077; Swedish Cancer Society, CAN 2015/251; CAN 2018/468; CAN 2018/550; Swedish Research Council, 2015-04170; 2019-01162We thank Drs. Weiqiang Dou, Mitsuharu Miyoshi, and Bin Wu (GE Healthcare), Drs. Queenie Chan, Weibo Chen, Shuguang Hu, Jochen Keupp, Eunju Kim, Kim van de Ven, Michael Wyss, Masami Yoneyama, Xuna Zhao, and Yansong Zhao (Philips Healthcare), Drs. Yi-Cheng Hsu, Patrick Liebig, Li Pan, Benjamin Schmitt and Yi Sun (Siemens Healthineers), and Dr. Stefano Casagranda (Olea Medical) for help and suggestions over the years. We thank Drs. Sotirios Bisdas and Laura Mancini (University College London Hospitals NHS Foundation Trust and UCL Queen Square Institute of Neurology, London, United Kingdom) for kindly providing their unpublished Figure 10D and related explanation. We also thank Dr. Wilfred W. Lam (Sunnybrook Research Institute) for many helpful discussions. Funding information: National Institutes of Health, Grant/Award Numbers: R01CA228188 and R01AG069179 (to J.Z.); R37CA248077 (to S.J.); P41EB029460 (to R.R.); P41EB015909 and R01EB015032 (to P.C.M.v.Z.); Swedish Research Council, Grant Numbers: 2015-04170 (to L.K.); 2019-01162 (to P.C.S.); Swedish Cancer Society, Grant Numbers: CAN 2015/251 and CAN 2018/550 (to L.K.); CAN 2018/468 (to P.C.S.); National Research Foundation of Korea (NRF), Grant number: 2014R1A1A1002716 (to S.S.A.); German Research Foundation (DFG), Grant number: 445704496 (to D.P.).
Funding Information:
German Research Foundation (DFG), 445704496; National Research Foundation of Korea (NRF), 2014R1A1A1002716; National Institutes of Health, P41EB015909; P41EB029460; R01AG069179; R01CA228188; R01EB015032; R37CA248077; Swedish Cancer Society, CAN 2015/251; CAN 2018/468; CAN 2018/550; Swedish Research Council, 2015‐04170; 2019‐01162 Funding information
Funding Information:
We thank Drs. Weiqiang Dou, Mitsuharu Miyoshi, and Bin Wu (GE Healthcare), Drs. Queenie Chan, Weibo Chen, Shuguang Hu, Jochen Keupp , Eunju Kim, Kim van de Ven, Michael Wyss, Masami Yoneyama, Xuna Zhao, and Yansong Zhao (Philips Healthcare), Drs. Yi‐Cheng Hsu, Patrick Liebig, Li Pan, Benjamin Schmitt and Yi Sun (Siemens Healthineers), and Dr. Stefano Casagranda (Olea Medical) for help and suggestions over the years. We thank Drs. Sotirios Bisdas and Laura Mancini (University College London Hospitals NHS Foundation Trust and UCL Queen Square Institute of Neurology, London, United Kingdom) for kindly providing their unpublished Figure 10D and related explanation. We also thank Dr. Wilfred W. Lam (Sunnybrook Research Institute) for many helpful discussions. Funding information: National Institutes of Health, Grant/Award Numbers: R01CA228188 and R01AG069179 (to J.Z.); R37CA248077 (to S.J.); P41EB029460 (to R.R.); P41EB015909 and R01EB015032 (to P.C.M.v.Z.); Swedish Research Council, Grant Numbers: 2015‐04170 (to L.K.); 2019‐01162 (to P.C.S.); Swedish Cancer Society, Grant Numbers: CAN 2015/251 and CAN 2018/550 (to L.K.); CAN 2018/468 (to P.C.S.); National Research Foundation of Korea (NRF), Grant number: 2014R1A1A1002716 (to S.S.A.); German Research Foundation (DFG), Grant number: 445704496 (to D.P.).
Publisher Copyright:
© 2022 The Authors. Magnetic Resonance in Medicine published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.
PY - 2022/8
Y1 - 2022/8
N2 - Amide proton transfer-weighted (APTw) MR imaging shows promise as a biomarker of brain tumor status. Currently used APTw MRI pulse sequences and protocols vary substantially among different institutes, and there are no agreed-on standards in the imaging community. Therefore, the results acquired from different research centers are difficult to compare, which hampers uniform clinical application and interpretation. This paper reviews current clinical APTw imaging approaches and provides a rationale for optimized APTw brain tumor imaging at 3 T, including specific recommendations for pulse sequences, acquisition protocols, and data processing methods. We expect that these consensus recommendations will become the first broadly accepted guidelines for APTw imaging of brain tumors on 3 T MRI systems from different vendors. This will allow more medical centers to use the same or comparable APTw MRI techniques for the detection, characterization, and monitoring of brain tumors, enabling multi-center trials in larger patient cohorts and, ultimately, routine clinical use.
AB - Amide proton transfer-weighted (APTw) MR imaging shows promise as a biomarker of brain tumor status. Currently used APTw MRI pulse sequences and protocols vary substantially among different institutes, and there are no agreed-on standards in the imaging community. Therefore, the results acquired from different research centers are difficult to compare, which hampers uniform clinical application and interpretation. This paper reviews current clinical APTw imaging approaches and provides a rationale for optimized APTw brain tumor imaging at 3 T, including specific recommendations for pulse sequences, acquisition protocols, and data processing methods. We expect that these consensus recommendations will become the first broadly accepted guidelines for APTw imaging of brain tumors on 3 T MRI systems from different vendors. This will allow more medical centers to use the same or comparable APTw MRI techniques for the detection, characterization, and monitoring of brain tumors, enabling multi-center trials in larger patient cohorts and, ultimately, routine clinical use.
UR - http://www.scopus.com/inward/record.url?scp=85129010947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129010947&partnerID=8YFLogxK
U2 - 10.1002/mrm.29241
DO - 10.1002/mrm.29241
M3 - Article
C2 - 35452155
AN - SCOPUS:85129010947
SN - 0740-3194
VL - 88
SP - 546
EP - 574
JO - Magnetic Resonance in Medicine
JF - Magnetic Resonance in Medicine
IS - 2
ER -